Trial Profile
A Randomized, Double-blind, Double-dummy, Active-drug-controlled, Parallel-group, Multicentre Acceptability and Safety Study of the Transfer From Subutex/Suboxone to RBP-6300 in Opioid-dependent Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Sponsors Reckitt Benckiser
- 30 Oct 2014 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
- 11 Apr 2014 New trial record